Optimizer III Targets Muscle Contractions To Treat Heart Failure; Enters Trial
This article was originally published in The Gray Sheet
Executive Summary
Impulse Dynamics is 80% enrolled in the U.S. pivotal trial of its Optimizer III cardiac contractility modulation therapy for the treatment of heart failure
You may also be interested in...
Impulse Dynamics’ Optimizer III
Developer of the cardiac contractility modulation (CCM) therapy for treatment of congestive heart failure completes enrollment in the 430-patient, FIX-HF-5 U.S. randomized clinical trial. The device resembles a pacemaker or implantable defibrillator, but instead of targeting heart rhythm it uses an electrical pulse to modulate the strength of heart muscle contraction (1"The Gray Sheet" Jan. 29, 2007, p. 11)...
Impulse Dynamics’ Optimizer III
Developer of the cardiac contractility modulation (CCM) therapy for treatment of congestive heart failure completes enrollment in the 430-patient, FIX-HF-5 U.S. randomized clinical trial. The device resembles a pacemaker or implantable defibrillator, but instead of targeting heart rhythm it uses an electrical pulse to modulate the strength of heart muscle contraction (1"The Gray Sheet" Jan. 29, 2007, p. 11)...
Guidant Passes On Impulse Buy, Refines Business Grouping For Better Focus
Guidant will pass on an option to acquire exclusive rights to certain Impulse Dynamics experimental heart failure technologies in favor of in-house cardiac resynchronization therapies currently under clinical evaluation in the U.S. and Europe for heart failure.